Please login to the form below

Not currently logged in

Taking a leaf from their book

Can it be right, ask Neil and Tom Kendle, that online bookseller Amazon knows more about the interests of each of its 100 million customers than the average drug company knows about most of its key opinion leaders?

Neil and Tom KendleAmazon will frequently email those of us who are customers making suggestions for books or goods we might want to buy because it knows what we're interested in. Not only does this improve Amazon's sales but the customers feel they are more valued.

So, how can pharma use available information to find opinion leaders better suited to its needs and ensure that KOLs are invited to do things that they want to do - making the realtionship more effective and rewarding for both.

Is it enough to simply ask if an opinion leader has published three or more papers in major journals in the last three years? Or whether they have ever participated in a major trial? To make their relationship with opinion leaders more effective and rewarding for both parties, pharma should be asking KOLs what their research interests are, what journals do they publish in and how often are the different aspects of their work cited? After all, pharma wants doctors with a range of expertise and opinion leaders want to engage in activities that are most suited to their interests.

Increasingly, academics use standard mathematical methods to evaluate an individual's or organisation's work - known as bibliometrics or scientometrics. By making use of these methods ourselves we can more accurately measure the impact of someone's work using a system that is academically justifiable and is familiar to opinion leaders themselves.

Most of the information about opinion leaders that we collect on behalf of our client companies relates to them as individuals, but using mapping techniques largely derived from social science research, we can provide information about the relationships between opinion leaders and their peers: which individuals like to work together; who is well regarded by two rival research groups and could chair a meeting involving both?

Is there anything else we can learn from the sophisticated customer relationship management (CRM) systems of organisations like Amazon? As the name suggests, it is customer-centric. Many pharma companies seem to think only about what they want from opinion leader activities without ever having asked them if they are willing to travel as a speaker, like talking to the media,want to participate in advisory boards - or what their motivation is - do they want to raise their academic profile; or simply enjoy the variety of pharma-related activities? Opinion leaders tell us that companies seem reluctant to ask them such pointed questions, but when it does happen they feel like the relationship is appreciated and well-managed - that it is becoming a genuine partnership.

This approach implies that we are going to keep more detailed records on the opinion leaders than we currently do. Not everyone is comfortable with that. We must pay due regard to data protection of course but there is a tendency to be overly concerned about the ethics and perils of collating information on doctors. Just as we don't regard Amazon's records about us as some dark, Machiavellian repository of secrets, opinion leaders who know what intelligence a company keeps and understand how it is used, generally see this as eminently sensible and as an opportunity to ensure that they have a worthwhile relationship with that company.

This type of relationship pre-supposes a high level of transparency between the company and its opinion leaders. By doing this companies can promote a mutually beneficial relationship, where opinion leaders want to keep them informed because they know it is in their own interests to do so.

The Authors
Neil Kendle
is managing director and Tom Kendle is a project manager at Kendle Healthcare. They can be contacted at and or on 020 8941 6453

Innovative Thinkers in healthcare PR - a supplement from PMGroup

12th June 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...